Consolidated Statement Of Comprehensive Income

Nxera Pharma Co., Ltd. - Filing #7272710

Concept 2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
Consolidated statement of comprehensive income
Statement of comprehensive income
Profit (loss)
JPY
-4,838,000,000 JPY
-4,838,000,000 JPY
JPY
-4,838,000,000 JPY
JPY
JPY
-7,193,000,000 JPY
-7,193,000,000 JPY
JPY
JPY
-7,193,000,000 JPY
JPY
JPY
Other comprehensive income
Items that will not be reclassified to profit or loss
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income
807,000,000 JPY
668,000,000 JPY
Total of items that will not be reclassified to profit or loss
807,000,000 JPY
668,000,000 JPY
Items that may be reclassified to profit or loss
Exchange differences on translation of foreign operations
4,350,000,000 JPY
5,404,000,000 JPY
Total of items that may be reclassified to profit or loss
4,350,000,000 JPY
5,404,000,000 JPY
Other comprehensive income
JPY
5,157,000,000 JPY
5,157,000,000 JPY
5,157,000,000 JPY
JPY
JPY
JPY
6,072,000,000 JPY
6,072,000,000 JPY
JPY
6,072,000,000 JPY
JPY
JPY
JPY
Comprehensive income
JPY
319,000,000 JPY
319,000,000 JPY
5,157,000,000 JPY
-4,838,000,000 JPY
JPY
JPY
-1,121,000,000 JPY
-1,121,000,000 JPY
JPY
6,072,000,000 JPY
-7,193,000,000 JPY
JPY
JPY
Comprehensive income attributable to
Owners of parent
319,000,000 JPY
-1,121,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.